The Journal of Clinical Psychiatry

Supplementary Material

Article Title: Long-Term Safety, Tolerability, and Durability of Treatment Effect of Olanzapine and Samidorphan: Results of a 4-Year Open-Label Study

Authors: Jacob S. Ballon, MD, MPH; René S. Kahn, MD, PhD; Christina Arevalo, MS; Martin Dunbar, PhD; David McDonnell, MD; and Christoph U. Correll, MD

DOI Number: 10.4088/JCP.24m15511

LIST OF SUPPLEMENTARY MATERIAL FOR THE ARTICLE

1. Supplementary Text: The Enlighten Program

DISCLAIMER

SUPPLEMENTARY MATERIAL

Supplementary Text: The ENLIGHTEN Program

Results of the ENLIGHTEN Clinical Trials Program

The ENLIGHTEN clinical trial program was a series of phase 3, randomized, double-blind studies that tested antipsychotic efficacy and safety outcomes in patients treated with combined olanzapine and samidorphan (OLZ/SAM) versus olanzapine.[1-3] Overall, OLZ/SAM treatment was associated with disease improvement similar to that of olanzapine across studies.[1-3] In studies of ≥12 weeks' duration, treatment with OLZ/SAM was associated with significantly less weight gain than was olanzapine.[2,3] Although OLZ/SAM was associated with some degree of weight gain initially, weight stabilized after 4 to 6 weeks of OLZ/SAM treatment, while patients taking olanzapine monotherapy continued to gain weight.[2-4] Furthermore, in the ENLIGHTEN program's open-label extension studies, OLZ/SAM was associated with long-term stability of clinical symptoms and weight for up to 1 year of treatment.[5,6]

Summary of ENLIGHTEN Clinical Trial Criteria

ENLIGHTEN-1 and ENLIGHTEN-2 enrolled adult patients (aged 18–70 or 18–55 years, respectively) who met criteria for a *Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition*[7] (DSM-5) diagnosis of schizophrenia and had a baseline body mass index (BMI) between 18 and 40 kg/m^2 or 18 and 30 kg/m^2, respectively.[1,2] Enrollment criteria for ENLIGHTEN-Early were selected to capture patients who were early in the course of illness; eligible patients were between 16 and 40 years, had a primary DSM-5 diagnosis of schizophrenia, schizophreniform disorder, or bipolar I disorder and had a baseline BMI of <30 kg/m^2.[3] Patients who tested positive for any drug of abuse at study entry were excluded.

REFERENCES

1. Potkin SG, Kunovac J, Silverman BL, et al. Efficacy and safety of a combination of olanzapine and samidorphan in adult patients with an acute exacerbation of schizophrenia: outcomes from the randomized, phase 3 ENLIGHTEN-1 study. *J Clin Psychiatry*. 2020;81(2):19m12769.
2. Correll CU, Newcomer JW, Silverman B, et al. Effects of olanzapine combined with samidorphan on weight gain in schizophrenia: a 24-week phase 3 study. *Am J Psychiatry*. 2020;177(12):1168-1178.
3. Kahn RS, Kane JM, Correll CU, et al. Olanzapine/samidorphan in young adults with schizophrenia, schizophreniform disorder, or bipolar I disorder who are early in their illness: results of the randomized, controlled ENLIGHTEN-Early study. *J Clin Psychiatry*. 2023;84(3):22m14674.
4. Martin WF, Correll CU, Weiden PJ, et al. Mitigation of olanzapine-induced weight gain with samidorphan, an opioid antagonist: a randomized double-blind phase 2 study in patients with schizophrenia. *Am J Psychiatry*. 2019;176(6):457-467.
5. Yagoda S, Graham C, Simmons A, Arevalo C, Jiang Y, McDonnell D. Long-term safety and durability of effect with a combination of olanzapine and samidorphan in patients with schizophrenia: results from a 1-year open-label extension study. *CNS Spectr*. 2020;26(4):383-392.

6. Kahn RS, Silverman BL, DiPetrillo L, et al. A phase 3, multicenter study to assess the 1-year safety and tolerability of a combination of olanzapine and samidorphan in patients with schizophrenia: results from the ENLIGHTEN-2 long-term extension. *Schizophr Res*. 2021;232:45-53.
7. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition: DSM-5. Washington, DC: American Psychiatric Publishing; 2013.